Responses of mental stress–induced myocardial ischemia to escitalopram treatment: Background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial - 14/12/11
, Eric J. Velazquez, MD b, e, Zainab Samad, MD b, e, Maragatha Kuchibhatla, PhD c, e, Carolyn Martsberger, PhD a, e, Joseph Rogers, MD b, e, Redford Williams, MD a, e, Cynthia Kuhn, PhD d, e, Thomas L. Ortel, MD, PhD b, e, Richard C. Becker, MD b, e, Nicole Pristera a, e, Ranga Krishnan, MD a, e, Christopher M. O'Connor, MD, FACC b, eRésumé |
Background |
Mental stress–induced myocardial ischemia (MSIMI) is common in patients with clinically stable coronary heart disease (CHD) and is associated with poor outcomes. Depression is a risk factor of MSIMI. The REMIT trial investigates whether selective serotonin reuptake inhibitor (SSRI) treatment can improve MSIMI. The rationale and outline of the study are described.
Method |
In this single-center randomized clinical trial, adult patients with clinically stable CHD are recruited for baseline mental and exercise stress testing assessed by echocardiography. In addition, psychometric questionnaires are administered, and blood samples are collected for platelet activity analysis. Patients who demonstrate MSIMI, defined by new abnormal wall motion, ejection fraction reduction ≥8%, and/or development of ischemic ST change in electrocardiogram during mental stress testing, are randomized at a 1:1 ratio to escitalopram or placebo for 6 weeks. Approximately 120 patients with MSIMI are enrolled in the trial. The stress testing, platelet activity assessment, and psychometric questionnaires are repeated at the end of the 6-week intervention. The hypothesis of the study is that SSRI treatment improves MSIMI via mood regulation and modification of platelet activity.
Conclusion |
The REMIT study examines the effect of SSRI on MSIMI in vulnerable patients with CHD and probes some potential underlying mechanisms.
Le texte complet de cet article est disponible en PDF.Plan
| ClinicalTrials.gov identifier: NCT00574847. |
|
| James A. de Lemos, MD, served as guest editor for this article. |
Vol 163 - N° 1
P. 20-26 - janvier 2012 Retour au numéro
Article précédent
- International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
- Ajay K. Kakkar, Iris Mueller, Jean-Pierre Bassand, David A. Fitzmaurice, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gregory Y.H. Lip, Lorenzo G. Mantovani, Freek W.A. Verheugt, Waheed Jamal, Frank Misselwitz, Sophie Rushton-Smith, Alexander G.G. Turpie
- A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder
- William B. White, Deborah Grady, Linda C. Giudice, Scott M. Berry, Joanne Zborowski, Michael C. Snabes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?